Argent Biopharma Limited has released a press release.
CimetrA anti-inflammatory pre-clinical study results
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Argent Biopharma
- Glioblastoma pre-clinical trial results
- Cognicann Clinical Trial Results
- Response to ASX Aware Query
- Patent Granted for CannEpiL SNEDDS
- March 2022 Quarterly Activity and Cash Flow Reports
Later from Argent Biopharma
- Approvals received for South African CimetrA Clinical Trial
- Long COVID Study Results for ArtemiC Support
- June Quarter Activities and Cash Flow Report
- Amended June Quarterly Reports (amended App. 4C)
- Strategic Acquisition of 40% interest in ZAM Software Ltd
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma